NanoViricides (NYSE American: NNVC), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, is in the spotlight in the most recent episode of the PODD podcast. The company announced that president and executive chair Anil R. Diwan, PhD, was interviewed during the Oct. 11 episode of the program, which was released on PharmaTalkRadio. During the interview, Diwan discussed the company’s proprietary nanoviricides technology platform as well as its potentially revolutionary broad-spectrum antiviral clinical drug candidate, NV-387. According to the announcement, based on animal model studies, NV-387 exhibits potential to completely revolutionize the treatment of viral infections, much like penicillin changed the treatment of bacterial infections decades ago.
To listen to the episode, visit https://ibn.fm/FEnR7
To view the full press release, visit https://ibn.fm/vRcMA
About NanoViricides Inc.
NanoViricides is a clinical-stage company that is creating special-purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide(TM) class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma Inc. The company has a Memorandum of Understanding (“MOU”) with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MOU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. To learn more about the company, visit www.NanoViricides.com.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is powered by IBN